ZAMRA STRENGTHENS CAPACITY IN THE REGULATION OF BIOSIMILARS

The Zambia Medicines Regulatory Authority (ZAMRA) successfully conducted a five-day training workshop for its assessors from 22nd to the 26th of September 2025, focusing on the regulation of biological products and biosimilars.

For decades, biologic medicines have transformed the treatment of cancer, autoimmune disorders, and rare diseases.

Today, biosimilars are further reshaping healthcare globally by expanding access to quality, safe, and effective therapies for both human and animal health.

As these products become increasingly complex, ensuring they meet rigorous international regulatory standards is vital.

The workshop, which was facilitated by Mr. Charlton Tatenda - Dossier Assessment Specialist from the Botswana Medicines Regulatory Authority (BOMRA), provided participants with technical expertise to, among other things:

1. Enhance regulatory oversight of biological products

2. Shorten registration timelines

3. Improve access to life-saving medicines for the Zambian public

Through such initiatives, ZAMRA reaffirms its commitment to safeguarding public health while promoting innovation in medicines regulation.

Story by Lister M. Mutukwa - PRO